CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)Seeking Alpha • 05/12/25
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/12/25
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockGlobeNewsWire • 05/12/25
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)GlobeNewsWire • 05/12/25
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/25
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025GlobeNewsWire • 05/05/25
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual MeetingGlobeNewsWire • 04/28/25
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 03/11/25
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/06/25
CytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 03/06/25
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare ConferenceGlobeNewsWire • 03/05/25
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?Zacks Investment Research • 03/04/25
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025GlobeNewsWire • 02/27/25
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong BuyZacks Investment Research • 01/07/25
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateGlobeNewsWire • 01/06/25
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 12/16/24
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/27/24
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a TurnaroundZacks Investment Research • 11/19/24
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/07/24
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/24